

Itolizumab

Chemical Properties

CAS No. : 1116433-11-4
Formula:
Molecular Weight:
Appearance: no data available
Storage: store at low temperature
store at -80°C

Biological Description

Description	Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that humanizes the extracellular SRCR distal domain 1 of CD6. Itolizumab slows T cell proliferation and inhibits the production of pro-inflammatory cytokines. Itolizumab can be used to study conditions as diverse as psoriasis, rheumatoid arthritis (RA) and COVID-19 disease.
Targets(IC50)	Others
In vitro	Inhibiting T cell proliferation, Itolizumab is effective at a concentration of 100 µg/mL[1]. In PBMCs, Itolizumab (0-100 µg/mL) inhibits Treg polarization and enhances the acquisition of the Th1 phenotype[1]. During overnight culture of PBMCs, Itolizumab at 40 µg/mL reduces CD26hiCD161+CD8+T cells[2]. In PBMCs stimulated in Th17 polarizing conditions, Itolizumab at 40 µg/mL for 3-12 days reduces the expression of IL-17 and IFN-γ[3].
In vivo	In a humanized xenograft mouse model of Graft Vs Host Disease (GVHD), Itolizumab demonstrates therapeutic efficacy when administered intraperitoneally at doses of 60 µg or 300 µg daily[4].

Reference

Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. [Content Brief]

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481